Cargando…
The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma
Proteasome inhibitors, such as bortezomib, are first-line therapy against multiple myeloma (MM). Unfortunately, patients frequently become refractory to this treatment. The transcription factor NRF1 has been proposed to initiate an adaptation program that regulates proteasome levels. In the context...
| Autores principales: | , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Nature Publishing Group UK
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9120136/ https://www.ncbi.nlm.nih.gov/pubmed/35589686 http://dx.doi.org/10.1038/s41419-022-04925-3 |